BIOCRYST PHARMACEUTICALS INC 4

Director Jill C. Milne received 1,288 shares of BioCryst Pharmaceuticals (BCRX) common stock as a stock retainer in lieu of cash compensation.

On August 31, 2026, BioCryst Pharmaceuticals Inc. director Jill C. Milne received 1,288 shares of common stock at an implied price of $9.70 per share, issued in lieu of her full quarterly cash board retainer of $12,500. This represents an equity-based compensation award rather than an open-market purchase or sale, and following the transaction she directly owns 33,226 shares of BioCryst common stock. The award aligns the director’s compensation more closely with shareholder interests but does not independently signal a discretionary change in her investment stance.

Filing Facts

CIK

882796

Ticker

BCRX

Form

4

Source Type

fda

Accession

0000882796-26-000063

Alert Tier

5